New Drug Reviews
1 Results
- Pharmacotherapy New drug review
Eribulin Mesylate (E7389): Review of Efficacy and Tolerability in Breast, Pancreatic, Head and Neck, and Non–Small Cell Lung Cancer
Clinical TherapeuticsVol. 34Issue 7p1467–1473Published online: June 27, 2012- Sarah L. Scarpace
Cited in Scopus: 17Eribulin mesylate is a halichondrin B analogue that acts as a nontaxane microtubule dynamics inhibitor. Eribulin was approved in the United States in 2010 for the treatment of metastatic breast cancer for patients who have received at least 2 metastatic breast cancer chemotherapeutic regimens, including an anthracycline and a taxane. Eribulin is administered as a single agent at 1.4 mg/m2 IV for 2 to 5 minutes on days 1 and 8 of a 21-day cycle.
